Article thumbnail

Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions

By Sarah Kleijnen, Elisabeth George, Scott Goulden, Anne d'Andon, Pauline Vitré, Boguslawa Osińska, Rafal Rdzany, Steffen Thirstrup, Belen Corbacho, Bence Z. Nagy, Hubert G. Leufkens, Anthonius de Boer and Wim G. Goettsch

Abstract

AbstractObjectiveAssessment of the effectiveness compared with alternative treatment(s) plays an important role in many jurisdictions in determining the reimbursement status of pharmaceuticals. This type of assessment is often referred to as a relative effectiveness assessment (REA) and is carried out by many jurisdictions. Increased sharing of information across jurisdictions may save costs and reduce duplication. The objective of this study was to explore the main similarities and differences in the major methodological aspects of REA in multiple jurisdictions.MethodsData were gathered with a standardized data extraction form by searching publicly available information and by eliciting information from representatives at relevant organizations.ResultsOf the initially included 35 jurisdictions, data were gathered for 29 jurisdictions. There seem to be substantial similarities on the choice of the comparator, the role of indirect comparisons, and preferred end points in REAs (except for the use of health state utilities). Jurisdictions, however, differ in whether effectiveness (usual circumstances of health care practice) is estimated in case no (comparative) effectiveness data are available and how this is done.ConclusionSome important methodological aspects for REA are approached in a similar way in many jurisdictions, indicating that collaboration on assessments may be feasible. Enhanced collaboration in the development of methods and best practices for REA between jurisdictions will be a necessary first step. Important topics for developing best practice are indirect comparisons and how to handle the gap between efficacy and effectiveness data in case good quality comparative effectiveness data are not yet available at the time of reimbursement decisions

Publisher: International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
Year: 2012
DOI identifier: 10.1016/j.jval.2012.04.010
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://s3.amazonaws.com/prod-... (external link)
  • https://s3-eu-west-1.amazonaws... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.